Evidence map›Paper›PMID 42395088›Full record

ArticleAmerican journal of preventive cardiology2026

Independent external validation and head-to-head comparison of guideline-recommended CVD risk prediction models.

Lum Kastrati, Eleftheria Maria Alexandri, Maurice Rupp, Lisa Koch, Jose Garcia-Tirado, Christos Nakas, David J Maron, David Herzig, Lia Bally

Abstract read
In one paragraph

Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lum KastratiDepartment of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Eleftheria Maria AlexandriLaboratory of Biometry, School of Agriculture, University of Thessaly, Volos, Greece.
Maurice RuppDepartment of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Lisa KochDepartment of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Jose Garcia-TiradoDepartment of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Christos NakasDepartment of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
David J MaronStanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, United States.
David HerzigDepartment of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Lia BallyDepartment of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular disease (CVD) prediction models recommended by guidelines are developed using different populations, predictors, and outcome definitions. The implications of this heterogeneity for risk estimation are unclear, and direct comparisons remain limited. Objectives: Head-to-head comparison of the performance and transportability of three guideline-endorsed CVD risk prediction models, focusing on their sex-specific performance. Methods: We evaluated models recommended by the American Heart Association (PREVENT), European Society of Cardiology (SCORE2), and the National Institute for Health and Care Excellence (QRISK3). Risk of bias was assessed using the PROBAST tool. External validation was performed using the UK Biobank (UKBB) in a primary analysis including all participants with complete data for all models, enabling direct comparison, and in a secondary analysis applying each model to participants meeting its original eligibility criteria. Model performance was assessed using Brier scores, Area Under the Receiver Operating Characteristic Curve (AUC), and calibration across original and alternative outcome definitions, stratified by sex. Results: The PREVENT, SCORE2, and QRISK3 models varied substantially in terms of predictors, populations, and outcome definitions. We used data from 502,157 UKBB participants for the external validation in the primary analysis. Overall predictive performance (discrimination & calibration), as measured by Brier scores, was generally better in females. The AUC (95% CI) ranged from 0.7092 (0.7090-0.7094) to 0.7468 (0.7465-0.7471) for female and 0.6813 (0.6812-0.6814) to 0.6946 (0.6945-0.6946) for male populations. Calibration was suboptimal, particularly for older individuals, with systematic overestimation of risk. The models showed consistent performance when applied to different outcomes. All models were at high risk of bias. Conclusion: Despite heterogeneity in populations, predictors, and outcome definitions, PREVENT, SCORE2, and QRISK3 showed similar performance in the UKBB. Future studies should focus on prospective and standardized definitions and assessment of candidate predictors and outcomes.

Indexed as

Cardiovascular diseaseClinical risk prediction modelsPersonalized medicinePrevention

Identifiers

PMID42395088
PMCPMC13326136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.